10 December 2020 in American Journal of Neuroradiology
BACKGROUND AND PURPOSE: Stent-assisted treatment techniques can be an effective treatment option for intracranial aneurysms. The aim of this study was to evaluate the periprocedural feasibility and safety of the new LVIS EVO stent for the treatment of intracranial aneurysms. MATERIALS AND METHODS: Patients with intracranial aneurysms treated with the LVIS EVO in 11 European neurovascular centers were retrospectively reviewed. Patient and aneurysm characteristics, procedural parameters, immediate grade of occlusion, and technical and clinical complications were assessed. RESULTS: Fifty-seven patients with 59 aneurysms were treated with the LVIS EVO device; 57.6% of the aneurysms were incidental; 15.3% were acutely ruptured; 15.3% were recanalized or residual aneurysms; and 11.9% were treated for symptoms other than acute hemorrhage. The most frequent aneurysm locations were the middle cerebral artery (25.4%) and the anterior communicating artery (22.0%). The rate of immediate successful deployment was 93.2%. In 6.8% (n = 4) of cases, additional in-stent angioplasty was needed. The immediate complete occlusion rate was 54.2%, while there was a residual aneurysm in 35.6% and a residual neck in 10.2%. Periprocedural technical complications occurred in 7/59 treatments (11.9%; the most frequent technical complication [n = 3] was thrombus formation), which all resolved completely without clinical sequelae. Postprocedural neurologic complications occurred after 4/59 treatments (6.8%; 2 transient ischemic attacks, 1 minor stroke, 1 major stroke), of which only 1 persistent complication was directly related to the procedure (minor stroke in the vascular territory distal to the stent). CONCLUSIONS: The LVIS EVO stent is a safe, feasible device for the treatment of intracranial aneurysms.
1 January 2022 in Journal Of Neuroradiology
Several studies have reported good long-term results in the occlusion of intracranial aneurysms with flow diverter treatment. The aim of this study was to report the safety and six-month follow-up outcomes using the new Surpass Evolve flow diverter in the treatment of intracranial aneurysms. Consecutive patients with intracranial aneurysm treated with Surpass Evolve flow diverter in two high-volume neurovascular centers between May 2019 and January 2020 were retrospectively reviewed. Procedure-related complications, aneurysm occlusion (O'Kelly-Marotta grading scale), and clinical outcomes were assessed. Twenty-nine patients with 30 aneurysms were included in the study. Favorable aneurysm occlusion (O'Kelly Marotta grading scale C-D) at six-month follow-up was achieved in 21/27 (78%) aneurysms. No clinical procedure related thromboembolic complications were encountered. Twenty-three out of 24 patients with unruptured aneurysms treated with Surpass Evolve remained clinically intact at clinical follow-up. There was one fatal hemorrhagic procedure-related complication (3%). In five patients with ruptured aneurysms, no early or late rebleeds occurred from the aneurysms. Surpass Evolve FD worked technically well with no intraprocedural thromboembolic complications and occlusion rates comparable to other FDs.
11 April 2026 in Journal of NeuroInterventional Surgery
Background Transradial access (TRA) has become an integral component of contemporary neurointerventional practice, offering reduced access site complications and improved patient comfort compared with transfemoral approaches. However, anatomical constraints intrinsic to the radial route continue to define the physiological boundaries of radial first strategies, underscoring the need for guide catheters that balance navigability, support, and access site safety. The Benchmark BMX81 guide catheter represents a radial compatible platform designed to address these challenges, but large multicenter data within a standardized radial first framework remain limited. Methods We conducted a multicenter, retrospective observational study across nine high volume European neurointerventional centers. Adult patients undergoing neuroendovascular procedures in which the BMX81 was selected as the primary guide catheter via a radial first strategy were included. Technical success was defined as completion of the planned procedure using transradial access. Access conversion and procedural abortion were analyzed within a safety oriented radial first framework. Complications were assessed descriptively. Results A total of 300 patients (mean age 64 years; 58.3% women) were included. Technical success was achieved in 289 cases (96.3%). Radial-to-femoral access conversion occurred in four cases (1.3%), and seven procedures (2.3%) were aborted. Neither conversion nor procedural abortion was attributable to intrinsic guide catheter failure but consistently reflected predefined anatomical constraints, including unfavorable great vessel geometry and severe proximal tortuosity. Access related complications were infrequent and predominantly minor, including radial artery spasm (1.7%), minor forearm hematoma (5.3%), and asymptomatic radial artery occlusion (3.3%). No guide catheter entrapment, procedure related stroke, or mortality was observed. Conclusions Within a mature radial first neurointerventional strategy, the BMX81 demonstrated high technical success and a favorable safety profile across a broad spectrum of procedures. These findings support a strategy driven interpretation of transradial outcomes, in which guide catheter performance reflects the interaction between anatomy, access strategy, and device design rather than an isolated technical attribute. The BMX81 appears to be a reliable platform when applied within anatomically informed radial first practice.